Brain Tumor Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

The Brain Tumor Diagnostics Market is Segmented by Diagnostic Type (Imaging Test, Lumbar Puncture, Biopsy, Molecular Testing, and Others), Tumor Type (Metastatic, Meningioma, Glioblastoma, Pituitary Endoma, and Others), End User (Hospitals, Diagnostics Centers, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD) for the above segments.

Brain Tumor Diagnostics Market Size

Brain Tumor Diagnostics Market Summary
share button
Study Period 2018 -2028
Market Size (2023) USD 2.10 Billion
Market Size (2028) USD 3.10 Billion
CAGR (2023 - 2028) 8.30 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Brain Tumor Diagnostics Market Analysis

The Brain Tumor Diagnostics Market size is estimated at USD 2.10 billion in 2023, and is expected to reach USD 3.10 billion by 2028, growing at a CAGR of 8.30% during the forecast period (2023-2028).

The COVID-19 pandemic had a major impact on the brain tumor diagnostics market. Diagnostic procedures were postponed at the beginning of the pandemic as the hospitals and surgeons were advised to postpone or cancel elective procedures. For instance, according to the study published by Computational and Structural Biotechnology Journal in January 2021, malignant juvenile brain tumors are known for their rapid growth, necessitating early detection and treatment. As a result, delaying diagnosis may damage its effectiveness, lowering patient survival rates. This has further impacted the growth of the brain tumor diagnostics market during the pandemic.

Moreover, Brain Tumor Research, a research organization, reported a drastic delay in the diagnosis and treatment approaches, such as chemotherapy and radiotherapy for different types of brain tumors. However, the market is gradually stabilizing as COVID-19 cases are declining, resulting in the return of the normal demand levels for brain tumor diagnostics. Thus, COVID-19 is expected to significantly impact the brain tumor diagnostics market over the forecast period.

Factors such as the increasing prevalence of neurological disorders and cancers and the rising number of smokers are expected to drive the growth of the market over the forecast period. For instance, according to the estimates of the American Cancer Society, in 2023, about 24,810 malignant tumors of the brain or spinal cord will be diagnosed in the United States. This increase in cancer cases is expected to drive the overall brain tumor diagnostics market. Glioblastoma is an aggressive form of a brain tumor which occurs mostly in adults. It can also occur in children, but very rarely. It grows fast and spreads quickly. Quick diagnosis and treatment are necessary, as it is a fatal disorder.

Moreover, there is a rising prevalence of brain cancer across the world. For instance, according to an article published by netmed.com, in June 2022, around 330,000 children and adults globally were diagnosed with cancer of the Central Nervous System in a year. In India, central nervous system (CNS) cancer ranges from 5 to 10 per 100,000 people, with a rising trend and accounts for 2% of cancer. Thus, the increasing prevalence of brain tumors is one of the major factors augmenting the growth of the market.

Therefore, the factors mentioned above are attributed collectively to the studied market growth over the forecast period. However, high cost associated with diagnosis are projected to hamper the market growth slightly over the forecast period.

Brain Tumor Diagnostics Market Trends

MRI segment is Expected to Hold a Significant Share in the Brain Tumor Diagnostics Market

Magnetic resonance imaging (MRI)is a medical imaging technique used in radiology to produce pictures of the anatomy and the body's physiological processes. These pictures are further used to diagnose and detect the presence of abnormalities in the body. Dominant share is retained by the MRI segment owing to the attributes such as high application in the diagnosis of brain tumors. The rising prevalence of brain cancer cases worldwide is expected to drive the demand for the brain tumor diagnostics market over the forecast period. For instance, according to the Canadian Cancer Society, updated in May 2022, It was estimated that in 2022, 3,200 Canadians will be diagnosed with brain and spinal cord cancer, including 1,850 men and 1,350 women.

Furthermore, the increasing adoption of MRI systems is due to the establishment of new facilities in different countries worldwide. For instance, in November 2021, a sophisticated MRI facility was launched at the National Brain Research Centre (NBRC), Manesar, in Haryana, India. The National Brain Research Centre (NBRC) is India's premier institute dedicated to neuroscience research and education, and the MRI Scanner PRISMA 3T MRI from Siemens was installed at the facility.

Moreover, in February 2023, Case Western Reserve University was awarded a grant of USD 3 million to advance novel MRI and software technology for brain tumor diagnosis. This will eventually allow personalized treatment planning to improve patient outcomes.

Therefore, the factors mentioned above are expected to drive segmental growth in the market during the forecast period.

Brain Tumor Diagnostics Market: Estimated Cases of Brain or Spinal Cord Cancer, United States, 2023

North America is Anticipated to Register a Significant Growth in Brain Tumor Diagnostics Market

The North American brain tumor diagnostics market is projected to have a significant share over the forecast period. The United States is anticipated to lead the market. This is attributed to the developed healthcare industry, coupled with rising awareness regarding advanced technologies among the population in this region. For instance, according to the American Brain Tumor Association, more than 84,000 people were diagnosed with a primary brain tumor in 2021, and approximately 18,000 people died in 2021 as a result of a primary malignant brain tumor. In addition, according to the same source, more than 28,000 children in the United States will be diagnosed with a brain tumor in 2021. The rising prevalence of brain tumors is expected to drive the growth of this region.

Further, the introduction and launch of new and advanced diagnostics devices in the country by the key market players in the area are expected to augment the growth of the market in the region. For instance, in December 2021, ADM Diagnostics Inc. received FDA clearance for CorInsights MRI. CorInsights MRI provides quantitative information about brain tissue volume for radiologists, neurologists, and clinical researchers. Such launches are propelling the growth of the market in the region.

Thus, owing to the aforementioned factors, the North American brain tumor diagnostics market will likely grow significantly during the forecast period.

Brain Tumor Diagnostics Market: Brain Tumer Diagnostics Market - Growth Rate by Region

Brain Tumor Diagnostics Industry Overview

The brain tumor diagnostics market is consolidated in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known,, including GE Healthcare, Koninklijke Philips N.V., Siemens Healthcare GmbH, Fujifilm Corporation, and Hitachi, Ltd, among others.

Brain Tumor Diagnostics Market Leaders

  1. GE Healthcare

  2. Koninklijke Philips N.V.

  3. Siemens Healthcare GmbH

  4. Fujifilm Corporation

  5. Hitachi, Ltd.

*Disclaimer: Major Players sorted in no particular order

Brain Tumor Diagnostics Market Concentration

Brain Tumor Diagnostics Market News

  • February 2023: Roche announced the launch of the IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibody and the ATRX Rabbit Polyclonal Antibody to identify mutation status in patients diagnosed with brain cancer.
  • In January 2023: Datar Cancer Genetics Inc. received FDA breakthrough device designation for the TriNetra-Glio blood test to help in the diagnosis of brain tumors.

Brain Tumor Diagnostics Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Neurological Disorders and Cancers

      2. 4.2.2 Rising Number of Smokers

    3. 4.3 Market Restraints

      1. 4.3.1 High Costs Associated with Diagnosis

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 5.1 By Diagnostic Type

      1. 5.1.1 Imaging Test

        1. 5.1.1.1 MRI

        2. 5.1.1.2 CT Scan

        3. 5.1.1.3 Other

      2. 5.1.2 Lumbar Puncture

      3. 5.1.3 Biopsy

      4. 5.1.4 Molecular Testing

      5. 5.1.5 Others

    2. 5.2 By Tumor Type

      1. 5.2.1 Metastatic

      2. 5.2.2 Meningioma

      3. 5.2.3 Glioblastoma

      4. 5.2.4 Pituitary Endoma

      5. 5.2.5 Others

    3. 5.3 By End User

      1. 5.3.1 Hospitals

      2. 5.3.2 Diagnostics Centers

      3. 5.3.3 Others

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 GE Healthcare

      2. 6.1.2 Koninklijke Philips N.V.

      3. 6.1.3 Siemens Healthineers

      4. 6.1.4 Fujifilm Corporation

      5. 6.1.5 Hitachi, Ltd.

      6. 6.1.6 Hologic, Inc.

      7. 6.1.7 NantOmics

      8. 6.1.8 Thermo Fisher Scientific

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

Brain Tumor Diagnostics Industry Segmentation

As per the scope of the report, a brain tumor is an abnormal growth of cells in or around your brain. The diagnosis of a brain tumor involves a physical exam, neurological exam, imaging of the brain or spine (depending on the patient's symptoms), and a specific biopsy based on the location of the tumor. 

The brain tumor diagnostics market is segmented by diagnostic type (imaging test, lumbar puncture, biopsy, molecular testing, and others), tumor type (metastatic, meningioma, glioblastoma, pituitary adenoma, and others), end user (hospitals, diagnostics centers, and others), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD) for the above segments.

By Diagnostic Type
Imaging Test
MRI
CT Scan
Other
Lumbar Puncture
Biopsy
Molecular Testing
Others
By Tumor Type
Metastatic
Meningioma
Glioblastoma
Pituitary Endoma
Others
By End User
Hospitals
Diagnostics Centers
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

You can also purchase parts of this report. Do you want to check out a section wise price list?

Brain Tumor Diagnostics Market Research FAQs

The Brain Tumor Diagnostics Market size is expected to reach USD 2.10 billion in 2023 and grow at a CAGR of 8.30% to reach USD 3.10 billion by 2028.

In 2023, the Brain Tumor Diagnostics Market size is expected to reach USD 2.10 billion.

GE Healthcare, Koninklijke Philips N.V., Siemens Healthcare GmbH, Fujifilm Corporation and Hitachi, Ltd. are the major companies operating in the Brain Tumor Diagnostics Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2023-2028).

In 2023, the North America accounts for the largest market share in Brain Tumor Diagnostics Market.

Brain Tumor Diagnostics Industry Report

Statistics for the 2023 Brain Tumor Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Brain Tumor Diagnostics analysis includes a market forecast outlook to for 2023 to 2028) and historical overview. Get a sample of this industry analysis as a free report PDF download.

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!